bexarotene(redirected from LGD1069)
a retinoid that modulates transcription and expression of genes involved in cellular differentiation and proliferation; used as an antineoplastic in the treatment of cutaneous T-cell lymphoma, administered orally. It is also used topically in the treatment of cutaneous lesions of T-cell lymphomas and Kaposi's sarcoma.
bexaroteneA retinoid that binds to retinoid X receptors, upregulating their activity by either removing negative transcription control or by facilitating transcription. It is FDA-approved for treating cutaneous T cell lymphoma, and has been used off label for lung and breast cancer, and Kaposi sarcoma.
Adverse effects Similar to hypervitaminosis A—headache, nausea, vomiting, lip inflammation, mucous-membrane dryness, joint pain, scaly skin, hyperlipidaemia